12:00 AM
May 21, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Aes-103 5-hydroxymethyl-2-furfural: Phase I/IIa started

AesRx began a double-blind, placebo-controlled, U.S. Phase I/IIa trial to evaluate single ascending-doses of oral Aes-103 in 18 patients with stable sickle cell disease. Aes-103 has...

Read the full 106 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >